市場調查報告書

急性腎功能衰竭(ARF):市場考察,流行病學,市場預測 (2027年)

Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2028

出版商 DelveInsight Business Research LLP 商品編碼 524369
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
急性腎功能衰竭(ARF):市場考察,流行病學,市場預測 (2027年) Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2028
出版日期: 2019年01月01日內容資訊: 英文 100 Pages
簡介

主要7個國家急性腎功能衰竭(ARF)的整體罹患數2016年151萬6,635人被推算,同年的急性腎功能衰竭市場估算為83億9,200萬美元。

本報告提供急性腎功能衰竭(ARF)市場相關調查,提供疾病概要,主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的市場趨勢,市場規模的變化與預測(過去2年·今後10年份),總括性彙整潛在成長性,促進·阻礙因素分析,開發中治療藥的簡介,目前未滿足需求等資訊。

目錄

第1章 主要考察

第2章 急性腎功能衰竭市場概要

  • 市場佔有率(實際成果值)
  • 市場佔有率(預測值)

第3章 疾病的背景和概要:急性腎功能衰竭(ARF)

  • 簡介
  • 症狀
  • 急性腎功能衰竭的種類
  • 病期分類
  • 風險因素
  • 病因
  • 病理學
  • 診斷
  • 管理

第4章 流行病學和患者人口

  • 主要的觀察
  • 人口與預測參數
  • 主要7個國家急性腎功能衰竭的罹患數
  • 主要7個國家急性腎功能衰竭的罹患數(實際成果值)
  • 主要7個國家急性腎功能衰竭的罹患數(預測值)

第5章 急性腎功能衰竭的流行病學

第6章 美國

  • 前提和根據
  • 美國的急性腎功能衰竭的罹患數
  • 美國的急性腎功能衰竭的住院數量:性別
  • 美國的急性腎功能衰竭的罹患數:各病期

第7章 歐盟5國

  • 前提和根據
  • 德國
    • 德國的急性腎功能衰竭的罹患數
    • 德國的急性腎功能衰竭的住院數量:性別
    • 德國的急性腎功能衰竭的罹患數:各病期
  • 法國
    • 法國的急性腎功能衰竭的罹患數
    • 法國的急性腎功能衰竭的住院數量:性別
    • 法國的急性腎功能衰竭的住院數量:各病期
  • 義大利
    • 義大利的急性腎功能衰竭的住院數量
    • 義大利的急性腎功能衰竭的住院數量:性別
    • 義大利的急性腎功能衰竭的住院數量:各病期
  • 西班牙
    • 西班牙的急性腎功能衰竭的住院數量
    • 西班牙的急性腎功能衰竭的住院數量:性別
    • 西班牙的急性腎功能衰竭的住院數量:各病期
  • 英國
    • 英國的急性腎功能衰竭的住院數量
    • 英國的急性腎功能衰竭的住院數量:性別
    • 英國的急性腎功能衰竭的住院數量:各病期

第8章 日本

  • 前提和根據
  • 日本的急性腎功能衰竭的住院數量
  • 日本的急性腎功能衰竭的住院數量:性別
  • 日本的急性腎功能衰竭的住院數量:各病期

第9章 治療和預防

第10章 全球開發中產品

第11章 新藥治療(臨床第三階段試驗)

  • EA-230:Exponential Biotherapies, Inc
    • 臨床開發
    • 臨床試驗資訊
    • 安全性和有效性
    • 優點與缺點
    • 產品簡介
  • Zemiglo:LG Life Sciences
  • RESCAP:Alloksys
  • BB3:Angion Biomedica
  • QPI-1002: Quark
  • recAP: AM Pharma

第12章 主要7個國家的急性腎功能衰竭(ARF)市場:市場規模

第13章 主要7個國家市場佔有率:新藥

第14章 主要7個國家市場佔有率:各國

第15章 主要7個國家市場佔有率:治療藥物別

  • 美國的急性腎功能衰竭(ARF)市場:市場規模
    • 美國的市場佔有率:新藥
  • 德國的急性腎功能衰竭(ARF)市場:市場規模
    • 德國的市場佔有率:新藥
  • 法國的急性腎功能衰竭(ARF)市場:市場規模
    • 法國的市場佔有率:新藥
  • 義大利的急性腎功能衰竭(ARF)市場:市場規模
    • 義大利的市場佔有率:新藥
  • 西班牙的急性腎功能衰竭(ARF)市場:市場規模
    • 西班牙的市場佔有率:新藥
  • 英國的急性腎功能衰竭(ARF)市場:市場規模
    • 英國的市場佔有率:新藥
  • 日本的急性腎功能衰竭(ARF)市場:市場規模
    • 日本的市場佔有率:新藥

第16章 治療費趨勢

第17章 市場成長要素

第18章 市場障礙

第19章 DelveInsight的服務內容

第20章 附錄

第21章 調查方法

第22章 免責聲明

第23章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0021

DelveInsight's 'Acute Renal Failure (ARF) - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Acute Renal Failure in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Acute Renal Failure from 2016 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2028

Acute Renal Failure - Disease Understanding and Treatment Algorithm

The DelveInsight Acute Renal Failure market report gives the thorough understanding of Acute Renal Failure by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Acute Renal Failure in the US, Europe, and Japan.

Acute Renal Failure Epidemiology

The Acute Renal Failure epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [incidence population of ARF, Sex-Specific Incident Hospitalization cases and Stage-wise Incidence of Acute Renal Failure] scenario in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2028.

According to DelveInsight, total incident cases of Acute Renal Failure in 7 major markets are found out to be 1,516,635 in 2016.

Acute Renal Failure Drug Chapters

This segment of the Acute Renal Failure report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

There are large windows of opportunity for Acute Kidney Injury (AKI): to prevent AKI, to treat AKI after its onset, and to halt progression to ESRD. The pharmaceutical industry is investing on clinical trials conducted in the cardiovascular space, yet is little reluctant to enter the kidney market as the overall market is driven by monitoring system followed by transplantation with a very small therapeutic window. Detailed chapter for upcoming therapies EA-230 (Exponential Biotherapies), Zemiglo (LG Life Sciences), RESCAP (Alloksys), BB3 (Angion Biomedica), QPI-1002 (Quark) and recAP (AM Pharma) have been covered in the report.

Acute Renal Failure Market Outlook

The Acute Renal Failure market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Acute Renal Failure in 7MM was found to be USD 8,392 million in 2016, and is expected to increase at a CAGR of XX% from 2016-2028.

Acute Renal Failure Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Renal Failure Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Acute Renal Failure Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Acute Renal Failure Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Acute Renal Failure market
  • Organize sales and marketing efforts by identifying the best opportunities for Acute Renal Failure market
  • To understand the future market competition in the Acute Renal Failure market.

Table of Contents

1. Key Insights

2. Acute Renal Failure Market Overview at a Glance

  • 2.1. Market Share Distribution of Acute Renal Failure in 2016
  • 2.2. Market Share Distribution of Acute Renal Failure in 2028

3. Disease Background and Overview: Acute Renal Failure (ARF)

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Types of Acute Renal Failure
  • 3.4. Stages Classification
  • 3.5. Risk Factors
  • 3.6. Etiology
  • 3.7. Pathophysiology
  • 3.8. Diagnosis
  • 3.9. Management

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. Incident Cases of Acute Renal Failure in 7MM
  • 4.4. Incident Population of Acute Renal Failure in 7MM in 2016 (%)
  • 4.5. Incident Population of Acute Renal Failure in 7MM in 2025 (%)

5. Epidemiology of Acute Renal Failure

6. United States

  • 6.1. Assumptions and Rationale
  • 6.2. Incident Population of Acute Renal Failure in the United States
  • 6.3. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in the United States
  • 6.4. Stage-wise Incidence of Acute Renal Failure in the United States

7. EU5

  • 7.1. Assumptions and Rationale
  • 7.2. Incident Population of Acute Renal Failure in Germany
  • 7.3. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Germany
  • 7.4. Stage-wise Incidence of Acute Renal Failure in Germany
  • 7.5. France
    • 7.5.1. Incident Populations of Acute Renal Failure in France
    • 7.5.2. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in France
    • 7.5.3. Stage-wise Incidence Hospitalization cases of Acute Renal Failure in France
  • 7.6. Italy
    • 7.6.1. Incident Hospitalization cases of Acute Renal Failure in Italy
    • 7.6.2. Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Italy
    • 7.6.3. Stage-wise Incidence Hospitalization cases of Acute Renal Failure in Italy
  • 7.7. Spain
    • 7.7.1. Incident Hospitalization cases of Acute Renal Failure in Spain
    • 7.7.2. Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Spain
    • 7.7.3. Stage-wise Incidence of Acute Renal Failure in Spain
  • 7.8. United Kingdom
    • 7.8.1. Incident hospitalization cases of Acute Renal Failure in the UK
    • 7.8.2. Sex-Specific Incident hospitalization cases of Acute Renal Failure in the UK
    • 7.8.3. Stage-wise Incident hospitalization cases of Acute Renal Failure in the UK

8. Japan

  • 8.1. Assumptions and Rationale
  • 8.2. Incident Hospitalization cases of Acute Renal Failure in Japan
  • 8.3. Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Japan
  • 8.4. Stage-wise Incident hospitalization cases of Acute Renal Failure in Japan

9. Treatment and Prevention

10. Global Pipeline Products

11. Emerging Therapies (Phase III Drugs)

  • 11.1. EA-230: Exponential Biotherapies
    • 11.1.1. Clinical Development
    • 11.1.2. Clinical Trials Information
    • 11.1.3. Safety and Efficacy
    • 11.1.4. Advantages and Disadvantages
    • 11.1.5. Product Profile
  • 11.2. Zemiglo: LG Life Sciences
    • 11.2.1. Clinical Development
    • 11.2.2. Clinical Trials Information
    • 11.2.3. Safety and Efficacy
    • 11.2.4. Product Profile
  • 11.3. RESCAP: Alloksys
    • 11.3.1. Other Developmental Activities
    • 11.3.2. Clinical Development
    • 11.3.3. Clinical Trials Information
    • 11.3.4. Advantages and Disadvantages
    • 11.3.5. Product Profile
  • 11.4. BB3: Angion Biomedica
  • 11.5. Other Developmental Activities
  • 11.6. Clinical Trials Information
  • 11.7. Safety and Efficacy
  • 11.8. Product Profile
  • 11.9. QPI-1002: Quark
    • 11.9.1. Other Developmental Activities
    • 11.9.2. Clinical Development
    • 11.9.3. Clinical Trial Information
    • 11.9.4. Safety and Efficacy
    • 11.9.5. Advantages and Disadvantages
    • 11.9.6. Product Profile
  • 11.10. recAP: AM Pharma
    • 11.10.1. Other Developmental Activities
    • 11.10.2. Clinical Development
    • 11.10.3. Clinical Trial Information
    • 11.10.4. Safety and Efficacy
    • 11.10.5. Advantages and Disadvantages
    • 11.10.6. Product Profile

12. 7MM Market Size of Acute Renal Failure

13. 7MM Market Share by Emerging Therapies

14. 7MM Market Share by Countries

15. 7MM Patient Share by Therapies

  • 15.1. United States- Acute Renal Failure Market Size
    • 15.1.1. US Market Share by Emerging Therapies
  • 15.2. Germany- Acute Renal Failure Market Size
    • 15.2.1. Germany Market Share by Emerging Therapies
  • 15.3. France- Acute Renal Failure Market Size
    • 15.3.1. France Market Share by Emerging Therapies
  • 15.4. Italy- Acute Renal Failure Market Size
    • 15.4.1. Italy Market Share by Emerging Therapies
  • 15.5. Spain -Acute Renal Failure Market Size
    • 15.5.1. Spain Market Share by Emerging Therapies
  • 15.6. UK- Acute Renal Failure Market Size
    • 15.6.1. UK Market Share by Emerging Therapies
  • 15.7. Japan-Acute Renal Failure Market Size
    • 15.7.1. Japan Market Share by Emerging Therapies

16. Trends Observed in the cost of Therapies in Acute Renal Failure

17. Market Drivers

18. Market Barriers

19. DelveInsight Capabilities

20. Appendix

21. Report Methodology

  • 21.1. Sources Used

22. Disclaimer

23. About DelveInsight

List of Tables

  • Table 1: Total Incident Population of Acute Renal Failure in 7 MM (2016-2028)
  • Table 2: Incident Population of Acute Renal Failure in the United States (2016-2028)
  • Table 3: Sex-Specific Incident Hospitalization of Acute Renal Failure in the United States (2016-2028)
  • Table 4: Stage-wise Population of Acute Renal Failure in the United States (2016-2028)
  • Table 5: Incident Population of Acute Renal Failure in Germany (2016-2028)
  • Table 6: Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Germany (2016-2028)
  • Table 7: Stage-wise Incidence Population of Acute Renal Failure in Germany (2016-2028)
  • Table 8: Incident Population of Acute Renal Failure in France (2016-2028)
  • Table 9: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
  • Table 10: Stage-wise incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
  • Table 11: Incident Population of Acute Renal Failure in Italy (2016-2028)
  • Table 12: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
  • Table 13: Stage-wise Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
  • Table 14: Incident Hospitalization cases of Acute Renal Failure in Spain (2016-2028)
  • Table 15: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Spain (2016-2028)
  • Table 16: Stage-wise Incident cases of Acute Renal Failure in Spain (2016-2028)
  • Table 17: Incident hospitalization cases of Acute Renal Failure in the United Kingdom (2016-2028)
  • Table 18: Incident hospitalization cases of Acute Renal Failure in the United Kingdom (2016-2028)
  • Table 19: Stage-wise Incident hospitalization of Acute Renal Failure in the United Kingdom (2016-2028)
  • Table 20: Incident Hospitalization cases of Acute Renal Failure in Japan (2016-2028)
  • Table 21: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Japan (2016-2028)
  • Table 22: Stage wise Incident hospitalization cases of Acute Renal Failure in Japan (2016-2028)
  • Table 23: EA-230, Description, 2016
  • Table 24: Zemiglo, Clinical Trial Description, 2016
  • Table 25: bRESCAP, Clinical Trial Description, 2016
  • Table 26: BB3, Clinical Trial Description, 2016
  • Table 27: QPI-1002, Clinical Trial Description, 2016
  • Table 28: recAP, Clinical Trial Description, 2016
  • Table 29: 7MM Market Size of Acute Renal Failure (ARF) in USD, Million (2016-2028)
  • Table 30: 7MM Acute Renal Failure Sales by Therapies (2021-2027)
  • Table 31: MM Market Share of Acute Renal Failure by countries, (2016 & 2027)
  • Table 32: Global Patient Share by Therapies (2016 & 2025)
  • Table 33: US Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Table 34: US Acute Renal Failure Sales by Therapies (2021-2027)
  • Table 35: Germany Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Table 36: Germany Acute Renal Failure Sales by Therapies (2021-2027)
  • Table 37: France Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Table 38: France Acute Renal Failure Sales by Therapies (2021-2027)
  • Table 39: Italy Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Table 40: Italy Acute Renal Failure Sales by Therapies (2021-2027)
  • Table 41: Spain Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Table 42: Spain Acute Renal Failure Sales by Therapies (2021-2027)
  • Table 43: UK Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Table 44: UK Acute Renal Failure Sales by Therapies (2021-2027)
  • Table 45: Japan Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Table 46: Japan Acute Renal Failure Sales by Therapies (2021-2027)

List of Figures

  • Figure 1: Types of Acute Renal Failure
  • Figure 2: Risk factors associated with Acute Kidney Failure
  • Figure 3: Pathophysiology of AKI
  • Figure 4: Biomarkers of AKI
  • Figure 5: Total Incident Population of Acute Renal Failure in 7 MM (2016-2028)
  • Figure 6: Incident Population of Acute Renal Failure in the United States (2016-2028)
  • Figure 7: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in the United States (2016-2028)
  • Figure 8: Stage-wise Incident Population of Acute Renal Failure in the United States (2016-2028)
  • Figure 9: Incident Population of Acute Renal Failure in Germany (2016-2028)
  • Figure 10: Sex-Specific Incident Hospitalization cases of Acute Renal Failure in Germany (2016-2028)
  • Figure 11: Stage-wise Incidence Population of Acute Renal Failure in Germany (2016-2028)
  • Figure 12: Incident Population of Acute Renal Failure in France (2016-2028)
  • Figure 13: Sex- Specific Incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
  • Figure 14: Stage-wise Incidence Hospitalization cases of Acute Renal Failure in France (2016-2028)
  • Figure 15: Incident Population of Acute Renal Failure in Italy (2016-2028)
  • Figure 16: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
  • Figure 17: Stage-wise Incidence Hospitalization cases of Acute Renal Failure in Italy (2016-2028)
  • Figure 18: Incident Population of Acute Renal Failure in Spain (2016-2028)
  • Figure 19: Sex- Specific Incidence Hospitalization cases of Acute Renal Failure in Spain (2016-2028)
  • Figure 20: Stage wise Incidence of Acute Renal Failure in Spain (2016-2028)
  • Figure 21: Incident Population of Acute Renal Failure in the United Kingdom (2016-2028)
  • Figure 22: Sex-Specific Incident hospitalization cases of Acute Renal Failure in the United Kingdom (2016-2028)
  • Figure 23: Stage wise Incident hospitalization of Acute Renal Failure in the United Kingdom (2016-2028)
  • Figure 24: Incident Population of Acute Renal Failure in Japan (2016-2028)
  • Figure 25: Sex-Specific Incidence Hospitalization cases of Acute Renal Failure in Japan (2016-2028)
  • Figure 26: Stage wise Incident hospitalization cases of Acute Renal Failure in Japan (2016-2028)
  • Figure 27: Global Mortality of ARF
  • Figure 28: 7MM Market Size of Acute Renal Failure (ARF) in USD, Million (2016-2028)
  • Figure 29: 7MM Acute Renal Failure Sales by Therapies (2021-2027)
  • Figure 30: 7MM Market Share of Acute Renal Failure by countries (2016 & 2027)
  • Figure 31: Global Patient Share by Therapies (2016 & 2025)
  • Figure 32: US Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Figure 33: US Acute Renal Failure Sales by Therapies (2021-2027)
  • Figure 34: Germany Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Figure 35: Germany Acute Renal Failure Sales by Therapies (2021-2027)
  • Figure 36: France Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Figure 37: France Acute Renal Failure Sales by Therapies (2021-2027)
  • Figure 38: Italy Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Figure 39: Italy Acute Renal Failure Sales by Therapies (2021-2027)
  • Figure 40: Spain Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Figure 41: Spain Acute Renal Failure Sales by Therapies (2021-2027)
  • Figure 42: UK Market Size of Acute Renal Failure in USD, Million (2016-2028)
  • Figure 43: UK Acute Renal Failure Sales by Therapies (2021-2027)
  • Figure 44: Japan Market Size of Acute Renal Failure (ARF) in USD, Million (2016-2028)
  • Figure 45: Japan Acute Renal Failure Sales by Therapies (2021-2027)
  • Figure 46: Market Drivers
  • Figure 47: Market Barriers
Back to Top